SUMMARY A population survey of 258 unrelated white British subjects showed a polymorphism for the 4-oxidation of debrisoquine. 'Extensive metabolisers' (EM) and 'poor metabolisers' (PM) are recognisable, 8.9% of the population being PM. Nine pedigrees ascertained through PM probands show that the PM phenotype is an autosomal Mendelian recessive character. The EM phenotype is dominant and the degree of dominance has been estimated at 30%. PM subjects are more prone to hypotension during debrisoquine therapy. The alleles controlling this polymorphism appear to control the oxidation of other drugs.
The antihypertensive drug, debrisoquine, undergoes metabolic hydroxylation in man. The formation of the major metabolite, namely 4-hydroxydebrisoquine, displays polymorphism in the population.1 In this study, two well-resolved phenotypes were seen. The first was characterised by persons who 4-hydroxylated the majority of the drug and were thus designated extensive metabolisers (EM phenotype, about 95 % of the white British population). For these subjects, the metabolic ratio (MR), defined as % of dose as debrisoquine! % of dose as 4-hydroxy-debrisoquine excreted in the 0 to 8 hour urine, was of the range 0-01 to 9. In the second phenotype (poor metabolisers, PM, about 5% of British whites), MR values greater than 20 were observed, and thus these subjects had a relative inability to carry out debrisoquine 4-hydroxylation.
The few families studied suggested strongly that PM subjects were autosomal recessives.
In this paper, we describe a more extensive population study of white British subjects, together with further family data which uphold the resolution of the population into EM 
